8-(4-Hydroxyphenoxy)octanoic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 8-(4-Hydroxyphenoxy)octanoic acid
• 化学式: C₁₄H₂₀O₄
• 分子量: 252.31
• InChiKey: NJLNVKWPWHGEIM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  18
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• VALACYCLOVIR FORMULATIONS
  申请人：Oyewumi Moses

  公开号：US20090124639A1

  公开（公告）日：2009-05-14

  The present invention relates to valacyclovir formulations having improved bioavailability resulting in better efficacy and/or requiring less frequent administration.

  本发明涉及瓦拉西韦制剂，其具有改善的生物利用度，从而具有更好的疗效和/或需要更少的频繁给药。
• ARYLSULFANYL COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS
  申请人：Pusztay Stephen

  公开号：US20090258817A1

  公开（公告）日：2009-10-15

  Compounds and compositions for the delivery of active agents are provided. Methods of administration and preparation are also provided.

  提供用于传递活性剂的化合物和组合物。还提供了给药和制备方法。
• Oral GLP-1 Formulations
  申请人：Sarubbi Donald J.

  公开号：US20100016229A1

  公开（公告）日：2010-01-21

  The present invention provides pharmaceutical compositions comprising of at least one delivery agent and GLP-1. These pharmaceutical compositions facilitate the oral delivery of GLP-1, providing improved (e.g. increased) bioavailability of GLP-1 compared to administration of GLP-1 without a delivery agent.

  本发明提供了包含至少一种传递剂和GLP-1的药物组合物。这些药物组合物促进了GLP-1的口服给药，相比于没有传递剂的GLP-1给药，提高了GLP-1的生物利用度（例如，增加了生物利用度）。
• GLP-1 fusion peptides conjugated to polymer(s), their production and use
  申请人：Biocompatibles UK Limited

  公开号：EP1972349A1

  公开（公告）日：2008-09-24

  The present invention provides fusion peptides having GLP-1 activity and enhanced stability in vivo, in particular resistancy to dipeptidyl peptidase IV conjugated to polymers, thereby forming conjugate molecules. The fusion peptide of the conjugate molecule comprises as component (I) N-terminally a GLP-1(7-35, 7-36 or 7-37) sequence and as component (II) Gterminally a peptide sequence of at least 9 amino acids or a functional fragment, variant or derivative thereof. A synthetic polymer and/or a protein, e.g transferrin or albumin, is covalently or non-covalently bound to the fusion peptide to form the conjugate molecule. Component (II) is preferably a full or partial version of IP2 (intervening peptide 2). A preferred embodiment comprises the sequence GLP-1(7-35, 36 or 37)/IP2/GLP-1(7-35, 36 or 37) or GLP-2 and a polymeric component, e.g. a natural or non-natural polymer. The fusion peptide may be produced in engineered cells or synthetically and is e.g. conjugated to the polymeric component by chemical synthesis. The conjugate molecule may be used for the preparation of a medicament for treating various diseases or disorders, e.g. diabetes type 1 or 2, apoptosis related diseases or neurodegenerative disorders.

  本发明提供的融合肽具有 GLP-1 活性和更强的体内稳定性，特别是对二肽基肽酶 IV 的抗性，与聚合物共轭，从而形成共轭分子。共轭分子的融合肽包括作为组分（I）的 N 端 GLP-1（7-35、7-36 或 7-37）序列和作为组分（II）的 G 端至少 9 个氨基酸的肽序列或其功能片段、变体或衍生物。合成聚合物和/或蛋白质（如转铁蛋白或白蛋白）与融合肽共价或非共价结合，形成共轭分子。成分（II）最好是完整版或部分版的 IP2（中间肽 2）。优选的实施方案包括序列 GLP-1（7-35、36 或 37）/IP2/GLP-1（7-35、36 或 37）或 GLP-2 和聚合物成分，例如天然或非天然聚合物。融合肽可以在工程细胞中产生，也可以人工合成，例如通过化学合成与聚合物成分共轭。该共轭分子可用于制备治疗各种疾病或失调的药物，如 1 型或 2 型糖尿病、细胞凋亡相关疾病或神经退行性疾病。
• Compositions for delivering peptide YY and PYY agonists
  申请人：Dinh Steve

  公开号：US20050009748A1

  公开（公告）日：2005-01-13

  The present invention provides a composition (e.g., a pharmaceutical composition) comprising at least one delivery agent compound and at least one of peptide YY (PYY) and a PYY agonist. Preferably, the composition includes a therapeutically effective amount of peptide YY or the PYY agonist and the delivery agent compound. The composition of the present invention facilitates the delivery of PYY, a PYY agonist, or a mixture thereof and increases its bioavailability compared to administration without the delivery agent compound. PPY and PYY agonists possess activity as agents to reduce nutrient availability, including reduction of food intake

  本发明提供了一种组合物（例如药物组合物），该组合物包含至少一种递送剂化合物以及肽YY（PYY）和PYY激动剂中的至少一种。优选地，该组合物包括治疗有效量的肽 YY 或PYY 激动剂和递质化合物。本发明的组合物有利于PYY、PYY激动剂或其混合物的递送，与不使用递送剂化合物的给药相比，可提高其生物利用度。PY和PYY激动剂具有降低营养供应的活性，包括减少食物摄入量。